Dandelion's longitudinal, multimodal data incorporates newly
accessible unstructured data sources; provides deeper and broader
understanding of GLP-1 clinical benefits; and enables personalized
management of cardiometabolic disease.
NEW
YORK, May 14, 2024 /PRNewswire/ -- Dandelion
Health, a real-world data (RWD) and clinical AI platform powering
next-generation precision medicine and personalized care, today
launched its GLP-1 data library, the first truly multimodal
real-world clinical dataset built specifically to surface insights
and opportunities related to the GLP-1 receptor agonist drug
class.
"Our GLP-1 dataset will help
cardiometabolic disease enter its precision medicine era..." -
Elliott Green, Co-founder and CEO of
Dandelion Health.
Gathered from Dandelion's consortium of non-academic medical
center health system partners, the GLP-1 data library reflects the
full longitudinal patient records for millions of patients —
200,000 of whom are on various GLP-1 agonists. With data refreshed
quarterly, Dandelion's library combines data from the full patient
journey at a high level of fidelity, including structured EHR data
and all raw clinical data generated in the course of care (e.g.,
radiology images, ECG waveforms, and clinical notes). The combined
power of this dataset enables unprecedented insight into patient
journeys and the impact of GLP-1s.
Unlocking the depth of clinical data for GLP-1 treatment
discovery
Life sciences and other research organizations can use the GLP-1
data library for a range of use cases, including:
- Evaluating the quality of weight loss through biomarkers found
in body scans;
- Comparing the efficacy of treatments head-to-head across a
range of different real-world measures;
- Demonstrating GLP-1's therapeutic effects beyond current uses,
including secondary benefits derived from exploratory use or
demonstrated with additional data modalities;
- Quantifying any side effects associated with GLP-1 use;
and/or
- Developing precision-medicine tools to identify patients with
uncontrolled symptoms or to match patients to the right treatment
plans.
"Our GLP-1 dataset will help cardiometabolic disease enter its
precision medicine era. While the past few years have produced
great advancements in obesity care, there is still a wide gap
between cardiometabolic care today and the high-innovation,
high-investment, and deeply personalized care paradigms we see in
immunology and oncology," said Elliott
Green, Co-founder and CEO of Dandelion Health. "What got
those markets to where they are today was data — data that revealed
underlying mechanisms of disease, how individuals' diseases look
different, and consequently, how they might respond to therapy
differently."
About 80% of medical data is locked away in silos or is buried
in unstructured clinical data that is unusable without tools like
AI algorithms that interpret and structure data at scale. This data
includes a range of clinician notes in EHRs, imaging (e.g., MRIs,
CT scans) within picture and archiving communications systems
(PACS), echocardiogram (ECG) waveforms in vendor systems, and
more.
"Our goal was to curate a dataset that captures the full range
of benefits that this new class of emerging treatments can offer —
based on a larger and more representative patient population than
would traditionally be seen in clinical trials," said Shivaani
Prakash, Dandelion's Head of Data. "By making the rich,
multi-dimensional data offered by unstructured modalities available
and accessible — and connected to real-world treatment patterns and
outcomes — people who use the library can answer key questions
about the critical role that GLP-1–based treatments will play in
clinical care."
Dandelion's GLP-1 data library supporting existing research
Dandelion is already working with a number of AI developers and
researchers on unique proofs of concept using its GLP-1 data
library. One example includes researchers from a large academic
medical center who developed an algorithm that segments abdominal
CTs to quantify fat loss and muscle and bone preservation. The
project seeks to evaluate the impact of GLP-1s on overall body
composition — far more indicative of treatment efficacy compared to
weight loss, which is limited to what can be measured by structured
data like BMI.
Dandelion also has conducted its own research project using the
library's structured EHR data to evaluate GLP-1's efficacy across
real-world patient cohorts and demographic groups; the relationship
between persistence or duration of treatment and clinical outcomes;
as well as observable GLP-1 effects on other comorbidities that may
suggest adjacent indications. Dandelion will publish these findings
in a scientific preprint in Q2 2024.
Life sciences companies, clinical researchers, and AI developers
who are interested in working with Dandelion's platform and GLP-1
library are encouraged to reach out to the company.
About Dandelion Health
Dandelion Health is a health technology company powering the
next generation of healthcare.
Dandelion's Real-World Data and Clinical AI platform delivers
novel clinical insights at scale from rich, multimodal patient data
— enabling AI, medical device, and life sciences companies to
accelerate the entire product development lifecycle; improving
clinical outcomes; and enhancing patient lives. Founded by the
world's leading experts in healthcare and AI, Dandelion is a
diverse and growing consortium of leading healthcare systems from
across the United States. To learn
more, visit www.dandelionhealth.ai.
Media Contact
KT McGraw, Dandelion Health, 1
7818792395 N/A, media@dandelionhealth.ai, dandelionhealth.ai
View original content to download
multimedia:https://www.prweb.com/releases/dandelion-health-launches-glp-1-data-library-to-advance-precision-medicine-302142472.html
SOURCE Dandelion Health